Cartesian Therapeutics (RNAC) Stock
Clinical biotech developing safer options for repeated treatments. Here's the price, business snapshot, and what's worth knowing about Cartesian Therapeutics in October 2026.
Selecta Biosciences Inc (RNAC) is a clinical‑stage biotechnology company focused on immune‑tolerising nanoparticle platforms, notably ImmTOR and Synthetic Vaccine Particles (SVP). The technology is designed to modulate immune responses to biologics, gene therapies and vaccines with the aim of reducing anti‑drug antibodies and enabling safer repeat dosing. Investors should be aware that Selecta’s value is pipeline‑driven: clinical readouts, partnership deals and regulatory milestones are the main near‑term catalysts. With a market capitalisation around $241m, it is a small‑cap, high‑volatility company where financing activity and trial outcomes can materially affect the share price. Key risks include clinical failure, regulatory delay, competitive alternatives and dilution from capital raises. This summary provides general educational information and is not investment advice — investors should carry out further research, consider their risk tolerance and, if needed, consult a regulated financial adviser.
Cartesian Therapeutics (RNAC) Stock Forecast
Analyst price target, next 12 months
$36.62
+492.5% vs today's $6.18
Price range over the last 12 months
Close to its 12-month low
Analysts covering Cartesian Therapeutics have a consensus 12-month target of $36.62, above the current price of $6.18.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Cartesian Therapeutics' stock with a target price of $36.62, indicating significant growth potential.
Financial Health
Cartesian Therapeutics is generating modest revenue and cash flow, indicating stable but limited financial growth.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts Ahead
Clinical readouts and partner announcements can create meaningful share‑price moves, though outcomes are uncertain and can be volatile.
Platform Reach and Partners
The ImmTOR/SVP platforms target multiple therapeutic areas and potential collaborations could extend reach, while commercial success is not guaranteed.
Risk and Volatility
Small‑cap biotech stocks can swing widely on news and financing needs — suitable for investors who accept higher risk and a long time horizon.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
